{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:31:10Z","timestamp":1785796270734,"version":"3.56.0"},"reference-count":7,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100012331","name":"Flanders Innovation & Entrepreneurship","doi-asserted-by":"publisher","award":["HBC.2021.824"],"award-info":[{"award-number":["HBC.2021.824"]}],"id":[{"id":"10.13039\/100012331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SD8622N"],"award-info":[{"award-number":["1SD8622N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S18121N"],"award-info":[{"award-number":["1S18121N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.tips.2022.10.004","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T08:06:59Z","timestamp":1668413219000},"page":"64-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis"],"prefix":"10.1016","volume":"44","author":[{"given":"Giel","family":"Vanreppelen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Nysten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Baldewijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart","family":"Sillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Donders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1542-897X","authenticated-orcid":false,"given":"Patrick","family":"Van Dijck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2022.10.004_bb0005","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s40265-022-01734-y","article-title":"Oteseconazole: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2022.10.004_bb0010","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100055","article-title":"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis","author":"Sobel","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.tips.2022.10.004_bb0015","doi-asserted-by":"crossref","first-page":"880.e1","DOI":"10.1016\/j.ajog.2022.07.023","article-title":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","volume":"227","author":"Martens","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.tips.2022.10.004_bb0020","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2217\/fmb-2021-0173","article-title":"Oteseconazole: an advance in treatment of recurrent vulvovaginal candidiasis","volume":"16","author":"Sobel","year":"2021","journal-title":"Future Microbiol."},{"key":"10.1016\/j.tips.2022.10.004_bb0025","doi-asserted-by":"crossref","first-page":"e1518","DOI":"10.1093\/cid\/ciaa1204","article-title":"A randomized Phase 2 study of VT-1161 for the treatment of acute vulvovaginal candidiasis","volume":"73","author":"Brand","year":"2021","journal-title":"Clin. Infect."},{"key":"10.1016\/j.tips.2022.10.004_bb0030","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00341-19","article-title":"In vitro activities of the novel investigational tetrazoles VT1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans","volume":"63","author":"Nishimoto","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2022.10.004_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.934353","article-title":"Management of recurrent vulvovaginal candidosis: narrative review of the literature and European expert panel opinion","volume":"12","author":"Donders","year":"2022","journal-title":"Front. Cell. Infect. Microbiol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614722002309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614722002309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T21:57:31Z","timestamp":1778623051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614722002309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0165614722002309"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2022.10.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2022.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}